|
ctDNA-based mutational landscape following anti-EGFR antibodies in metastatic colorectal cancer (mCRC) to uncover novel resistance mechanisms in the CCTG CO.26 trial. |
|
|
No Relationships to Disclose |
|
Christopher J. O'Callaghan |
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Diaceutics; Janssen Diagnostics; Precision RxDx; Roche Canada |
Consulting or Advisory Role - Astellas Pharma; Janssen Diagnostics; LEK; Precision RxDx; Roche Canada |
|
Research Funding - AstraZeneca (Inst); Thermo Fisher Scientific (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Diagnostics; Roche Canada; Thermo Fisher Scientific |
|
|
Honoraria - Advanced Accelerator Applications; Ipsen |
Speakers' Bureau - Advanced Accelerator Applications |
Research Funding - Taiho Pharmaceutical (Inst) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health |
Stock and Other Ownership Interests - Guardant Health |
Patents, Royalties, Other Intellectual Property - Guardant Health |
|
|
Honoraria - Celgene; Ipsen; Roche; SERVIER; Taiho Pharmaceutical |
Consulting or Advisory Role - AstraZeneca; Celgene; SERVIER; Shire; Taiho Pharmaceutical |
Research Funding - AstraZeneca (Inst); Bayer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Eisai; Taiho Pharmaceutical |
Research Funding - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Merck; Novartis |
|
|
Consulting or Advisory Role - AMGEN; Bayer; Eisai; Ipsen; Novartis; Pfizer; Taiho Pharmaceutical |
Research Funding - Ipsen (Inst) |